A
4.57
0.03 (0.66%)
| Previous Close | 4.54 |
| Open | 4.52 |
| Volume | 740,842 |
| Avg. Volume (3M) | 1,443,256 |
| Market Cap | 258,549,120 |
| Price / Earnings (Forward) | 24.15 |
| Price / Sales | 0.830 |
| Price / Book | 0.580 |
| 52 Weeks Range | |
| Earnings Date | 4 Feb 2026 |
| Profit Margin | 0.66% |
| Operating Margin (TTM) | -32.88% |
| Diluted EPS (TTM) | 0.220 |
| Quarterly Revenue Growth (YOY) | 34.30% |
| Total Debt/Equity (MRQ) | 17.18% |
| Current Ratio (MRQ) | 4.32 |
| Operating Cash Flow (TTM) | 16.00 M |
| Levered Free Cash Flow (TTM) | -16.41 M |
| Return on Assets (TTM) | 0.62% |
| Return on Equity (TTM) | 2.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Aurora Cannabis Inc. | Mixed | Mixed |
AIStockmoo Score
-0.3
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -4.0 |
| Average | -0.33 |
|
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Institutions | 19.70% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Jan 2026 | Announcement | Aurora Cannabis to Host Third Quarter 2026 Investor Conference Call |
| 20 Jan 2026 | Announcement | Aurora Secures EU Community Plant Variety Rights for Two Proprietary Cannabis Varieties |
| 14 Jan 2026 | Announcement | Aurora Achieves Significant Progress in Disease Resistance Research |
| 18 Dec 2025 | Announcement | Aurora Launches Daily Special™ in Germany, Delivering High-Quality, Affordable Medical Cannabis to Patients |
| 11 Dec 2025 | Announcement | Aurora Expands Leading Portfolio of High-Potency Medical Flower Products in Poland |
| 08 Dec 2025 | Announcement | Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand |
| 02 Dec 2025 | Announcement | Aurora Announces Distribution Partnership with Leafio Australia |
| 12 Nov 2025 | Announcement | Rubicon Organics Announces Appointment of Glen Ibbott as CFO |
| 05 Nov 2025 | Announcement | Aurora Cannabis Announces Fiscal 2026 Second Quarter Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |